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Objective:  To  explore  the  clinicopathological  features  of  myeloid  sarcoma  (MS).
Methods:  We  retrospectively  analyzed  the  clinicopathological  features  of  patients  with  MS and  reviewed
the  relevant  literature.
Results: There were  39  patients  (20  male  and  19  female,  with  a ratio  of  1.1:1) aged 2–62  years  (median:
33  years;  mean:  33.4  years),  with  53.9%  patients  in the  21–50  years  age group.  The  clinical  manifestations
varied  and  were  dependent  on  the lesion  location.  Immunohistochemistry  and  special  staining  showed
that  the  positive  rates  for myeloperoxidase,  CD43, CD34,  CD117,  CD68,  Lysozyme,  CD99,  and  naphthol  AS-
D chloroacetate  esterase  were  92.1%  (35/38),  91.3%  (21/23),  44.8%  (13/29),  42.3%  (11/26),  61.1% (11/18),
100.0%  (5/5),  78.6%  (11/14),  and  55.6%  (10/18),  respectively.  Histologically,  the  cells  were  predominantly
arranged  diffusely,  and  the solitary  inﬁltrating  cells  may  show  an  acinus-like  arrangement,  while  some
cells were  arranged  in  linear  or “Indian  ﬁle”  pattern.  Obvious  small  nucleoli  were  seen  in most  cases.
The  nuclei  were  predominantly  round  or oval,  although  eccentric,  kidney-shaped,  and lobulated  nuclei
were  also  observed.  A  varied  number  of  eosinophilic  granulocytes  were  found in  most  cases.  The “starry
sky”  appearance  was  observed  in  a  few  patients.  Among  18  patients,  the  survival  rate  was  38.9% and
the  median  survival  time  was  28 months.  MS  occurred  following  allogeneic  stem  cell  transplantation  in
5  cases.  There  were  14 de-novo  (45.2%,14/31)  and  17  secondary  MS  (54.8%,  17/31).  As  for  de-novo  MS,
female  rates  was  higher  (64.3%  vs.  29.4%),  older  average  years  (41.4  vs.  31.1  years),  older  middle  years
(47.5  vs.32  years).
Conclusions:  The  combined  application  of morphology,  immunohistochemistry,  and  special  staining  may
facilitate  the  diagnosis  of this  malignancy.  Surgery  plus  chemotherapy  remains  the  most  common  treat-
ment for  MS. The  prognosis  of MS was bad.
© 2016  The  Author(s).  Published  by Elsevier  GmbH.  This  is  an  open  access  article  under  the CC. Introduction
Myeloid sarcoma (MS) is an extramedullary proliferation of
yeloid blasts. By deﬁnition, the inﬁltrates efface the underlying
issue architecture. Tumor cells lack of speciﬁc B- or T-cell mark-
rs, and express myeloid or myelomonocytic markers such as CD13,
D33, myeloperoxidase (MPO), CD14, or CD64. MS  also expresses
D68, CD117, CD34, lysozyme, CD43, CD163, etc [1]. MS  can occur
s an isolated lesion but also preceding, concurrently with, or fol-
owing myeloproliferative disorders [2]. According to the World
ealth Organization Classiﬁcation of Tumors of Hematopoietic and
ymphoid Tissues, MS  includes granulocytic sarcoma (GS), primi-
∗ Corresponding authors.
E-mail addresses: whqyy@sina.com (H.-Q. Wang), lijiek812@foxmail.com (J. Li).
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344-0338/© 2016 The Author(s). Published by Elsevier GmbH. This is an open access ar
d/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
tive monocytic sarcoma, and tumor composed of three blood cells
(white blood cells, red blood cells, and platelets). Among these
three types, GS has the highest proportion (accounting for ∼96.3%).
Primitive monocytic sarcoma is rare [3], and tumors composed
of three types of blood cells are even rarer. GS develops follow-
ing the extramedullary proliferation and inﬁltration of primitive or
immature granulocytes. The presence of myeloperoxidase in imma-
ture granulocytes means that the tumor may  become green after
air exposure. Thus, it is also known as chloroma. In the current
study, we retrospectively analyzed the clinicopathological data of
39 patients with MS  to facilitate the diagnosis and treatment of this
malignancy.ticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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Table  1
Disease-onset locations and clinical manifestations in 39 patients.
Locationsa n % Clinical manifestations
Cervical lymph nodes 7 16.3 Swelling of multiple superﬁcial lymph nodes
Inside and outside vertebral canal 6 14.0 Low back pain accompanied by lower limb
pain/numbness/weakness, hypoesthesia, urinary retention,
bloating, and constipation
Skin  and subcutaneous tissue 4 9.3 Several peanut-sized skin masses in the whole body
Mediastinum 3 7.0 Irritating dry cough
Uterus  3 7.0 Vaginal bleeding, menstrual disorders, and cervical bleeding
Left  ovary 2 4.7 Menstrual disorder
Salivary gland 2 4.7 Difﬁculty in opening mouth; numbness around the mouth
Left  testicle 2 4.7 Presented with suspected epididymitis
Gastrointestinal tract 2 4.7 Periumbilical pain, constipation, and incomplete intestinal
obstruction
Soft  tissue 2 4.7 Pain and numbness, along with correspondingly radiating pain
Nasal  passages 1 2.3 Nasal airway obstruction; bloody nasal discharge
Vestibule of larynx 1 2.3 Hoarseness
Right external auditory meatus 1 2.3 Bloody discharge
Retroperitoneal area 1 2.3 Painless mass
Spleen 1 2.3 Remarkably enlarged spleen; traumatic rupture of spleen
Right  liver 1 2.3 Hypoechoic nodule
Left  kidney 1 2.3 Low back pain/discomfort accompanied by urinary frequency
and dysuria
Abdominal cavity 1 2.3 Abdominal mass for over 10 years
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a Occurred at multiple locations in 4 cases.
. Materials and methods
We  retrospectively analyzed the clinicopathological data of 39
atients with MS  who were diagnosed in the Department of Pathol-
gy of the Chinese PLA General Hospital from October 2005 to April
015. The patients were aged 2–62 years (median: 33 years; mean:
3.4 years): 10 (25.6%) were aged ≤20 years, 21 (53.9%) 21–50 years,
nd 8 (20.5%) >50years. This means that most patients were middle-
ged. There were 20 men  and 19 women, yielding a male/female
atio of 1.1: 1.
Most tissue specimens for pathological examinations were
ray–white, gray–red, gray-yellow, or gray–brown; in one case
he tissue was pale green during intraoperative exploration but
urned gray–white after ﬁxation. The specimens were ﬁxed in 10%
eutral-buffer formalin solution, embedded in parafﬁn wax, sec-
ioned to 4 m,  and stained with hematoxylin and eosin (HE). A
umor of hematopoietic and lymphoid tissue was suspected, and
mmunohistochemistry and special histochemistry staining were
hen performed. Some patients also received genetic testing.
Immunohistochemistry was performed using an EnVision
Dako) two-step visualization method. After high temperature and
igh pressure citrate buffer retrieval, sections were developed with
iaminobenzidine (DAB) and counterstained with hematoxylin.
During naphthol ASD chloroacetate esterase (NAS-DCE) stain-
ng, the deparafﬁnized sections were put into the incubation
olution and incubated at room temperature for 30 min. After
he slides were rinsed with running water for 1 min  and then
ith distilled water again, nuclei were counterstained with 2%
ethyl green. The sections were gently washed with running
ater and air-dried, then maked be transparent with xylene, ﬁnally
ounted. The incubation solution was prepared as follows: 0.2 ml
-azo-pararosaniline was slowly added to 35 ml  0.067 M phosphate
uffer, with gentle shaking. When it was well mixed, 1 ml  NAS-
CE was added, with increasingly strong vibration and ﬁltrated
ollowing formation of pink precipitation.
SPSS17.0 software package was used for statistical analysis. Uni-
ariate survival analysis was  carried out according to Kaplan-Meier,
hereas differences in survival curves were assessed with the log-
ank test.Headaches, head swelling, and vomiting
3. Results
3.1. Clinical data
The disease-onset locations are shown in Table 1. The clinical
manifestations were diverse and related to the location, where
they caused symptoms of oppression and blockage (Table 1). The
non-speciﬁc symptoms included anemia, fatigue, dizziness, poor
appetite, fever, and swollen superﬁcial lymph nodes.
MS  occurred concurrently with acute myeloid leukemia (AML)
in 8 cases and chronic myeloid leukemia (CML) in 1. There were
7 cases of MS  which occurred following AML; In one of these
7 cases, GS was initially diagnosed in several bones, which was
treated with routine chemotherapy for acute non-lymphocytic
leukemia. One year after completion of chemotherapy, the patient
had a relapse, which was diagnosed as acute promyelocytic
leukemia. Haploidentical hematopoietic stem cell transplantation
(HSCT) was performed. Eleven months later, the patient devel-
oped extramedullary recurrence, which included GS in the central
nervous system and in the external auditory canal, followed by
intramedullary recurrence. In 5 cases, MS  occurred following
allogeneic HSCT (allo-HSCT) within 11 months to 11 years. Trans-
plantation was performed because of leukemia in 4 cases and
myelodysplastic syndrome (MDS) in 1 case with the longest interval
following allo-HSCT.
There were 14 cases de-novo MS  (45.2%, 14/31) and 17 sec-
ondary(54.8%, 17/31) excepting the other 8 outpatients without
medical history (Table 2). In 14 de-novo MS,  the patients were
aged 7–63 years (median:47.5 years; mean: 41.4 years). There
were 5 men  (35.7%, 5/14) and 9 women (64.3%, 9/14), yielding a
male/female ratio 1:1.8. In 17 secondary MS,  the patients were
aged 10–62 years (median 32 years; mean: 31.1 years). There
were 12 men  (70.6%, 12/17) and 5 women (29.4%, 5/17), yielding a
male/female ratio 2.4:1. As for de-novo MS,  female rates was higher
(64.3% vs. 29.4%), older average years (41.4 vs. 31.1 years), older
middle years (47.5 vs. 32 years).3.2. Pathological morphology
Histologically, the cells were mainly arranged diffusely with
poorly deﬁned borders, and the solitary inﬁltrating cells may  show
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Table 2
Results of routine blood test and bone marrow test.
Cases Routine blood test Bone marrow test De-novo or secondary
Hb (G/L) WBC  (x109/L) BPC (x109/L) Hyperplasia state Granulocytes:RBC others
1 144 7.22 218 Much active 4.58:1 No megakaryocyte production pattern De-novo
2  97 5.58 active De-novo
3  82 1.62 172 active 4.6:1 60.4% for promitive cells Secondary(concurrent with AML-M5)
4  80 2.89 114 Much active 120.5 20.8% for promitive cells, 30% for
promyelocytes
Secondary to AML-M3 after 4 years;
now reoccuring with AML  after
allo-HSCT 11w.
5  120 2.6 De-novo
6  106 5.92 160 Secondary to MDS  more than 11 years
after allo-HSCT
7  normal normal normal Secondary to AML
8  126 4.93 136 active 2.6:1 Each stage cells with roughly normal
proportion
De-novo
9  108 10.8 153 De-novo
10  105 11.53 78 27.23% for promitive cells Secondary(concurrent with AML-M2)
11  137 11.18 342 De-novo
12  133 11.34 178 De-novo
13  112 5.42 265 Much active 2.27:1 Each stage cell proportion was roughly
normal.
De-novo
14  normal normal normal De-novo
15  normal normal normal De-novo
16  106 7.59 54 Much active 78.0% for promitive cells Secondary(concurrent with AML-M2)
17  Much active 78.0% for promitive cells Secondary(concurrent with AML-M2)
18  43 127 8 Most active 16.45:1 Myelocyte and metamyelocyte radio
was slightly higher.
Secondary(concurrent with CML)
19  105 4.59 383 Much active 2.8% for promitive cells De-novo
20  85 111.25 110 Secondary(concurrent with AML)
21  96 2.0 127 Most active 31.7 56.0% for promitive cells Secondary to M5 after 86 months,
occuring 79 months after allo-HSCT;
concurrent with AML
22  normal normal normal Secondary to M3 after allo-HSCT
23  96 215.66 85 39.6% for promitive cells and
promonocytes
Secdonary to M4 after 10 months.
24  90 2.73 20 Secdonary to M1 after 31 months,
following 2 allo-HSCT
25  145 4.27 191 De-novo
26  Secdonary to AML(Outpatient)
27  109 34.5 12 Much active 90.0% for promitive cells Secondary(concurrent with AML-M5)
28  85 126 50 Most active 22% for promitive cells, 63.2% for
promonocytes
Secondary(concurrent with AML-M4)
29  74 2.44 91 Secondary(concurrent with AML-M3)
30  109 3.48 186 De-novo
31  110 4.25 205 De-novo
The other 8 outpatients werent included in the table. M0:minimally differentiated; M1:without maturation; M2:  with maturation;M3: acute promyelocytic leukemia; M4:acute myelomonocytic leukemia,; M5:acute monoblastic
leukemia and monocytic leukemia.
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Fig. 1. (A) The tumor cells varied in size, from small-round-shaped cells to megakaryocytes. The cytoplasm of middle-size cells was abundant with red stain and granular;
some  nuclei were eccentric. Cytoplasm of megakaryocytes was  also abundant with pale red stain, and lobulated nuclei were seen. (B) The arrangement of the cells were diffuse
and  crowded. Signet ring-like tumor cells were observed with vacuolated cytoplasm. Vesicular nuclei were common with small nucleoli. (C) The tumor cells were arranged
for  linear or “Indian ﬁle” pattern. The nuclei were irregular. Small nucleoli were seen. The stained cytoplasm was  pale. A few of eosinophilic granulocytes were found. Isolated
collagen in the mesenchyme were observed. (D) The tumor cells showed an acinus-like arrangement. The tumor cells were small and immature. Hyperchromatic nuclei with
small  nucleoli were seen. Kidney-shaped nuclei and a small amount of lobulated ones were visible. Plasmacytoid tumor cells were also observed. Nuclear chromatin was
ﬁne.  The cytoplasm was abundant which was  stained red and purple with granular. In some cases, the cytoplasm was dense and homogeneous. (E) The tumor invaded the
fat  tissue. The cells with poorly deﬁned borders presented widespread arrangement. Nuclear chromatin was  ﬁne with vesicular nuclei. 1–2 small nucleoli were observed.
Mitotic ﬁgures and apoptosis were common. Cytoplasm was  less to medium with pale red. (F) The tumor cells showed an acinus-like arrangement. Nuclear chromatin was
ﬁne  with vesicular nuclei. Small nucleoli were seen. A few of eosinophilic granulocytes were found. Isolated collagen in the mesenchyme were observed. HE staining x600,
respectively.
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n acinus-like arrangement, while some cells were arranged in lin-
ar or “Indian ﬁle” pattern, and a small proportion of cells showed
ord-like, nested, and patchy arrangements. In a few patients, a
obblestone-like distribution of the cells was observed. Most cells
ere small to medium-sized. Nuclear chromatin was  ﬁne, vesic-
lar nuclei were common, hyperchromatic nuclei were visible in
ome cases, and obvious small nucleoli were seen in most cases.
he nuclei were predominantly round or oval, although eccentric,
idney-shaped, and lobulated nuclei were also observed. The nuclei
ere irregular in part cases, and nuclear grooves were seen in sev-
ral patients. In a few cases, signet ring-like or plasmacytoid tumor43 (+) Envision method x600. (D) Bcl-2 ( + ) Envision method x200. (E) Ki-67 ( + )
cells were observed. Mitotic ﬁgures and apoptosis were common.
Cells of a few cases varied in size, and ones at different stages of
differentiation were seen. Cytoplasm was  abundant in most cases.
The stained cytoplasm was pale or slightly alkaline, pale red, red
and granular, or purple. A few cells had naked nuclei or vacuo-
lated cytoplasm, and in some cases, the cytoplasm was dense and
homogeneous. A varied number of eosinophilic granulocytes were
found in most cases, and some of them were still immature. Lym-
phocytic inﬁltration in the background was  seen in most cases.
Residual lymphoid tissues and lymphoid follicles were present in
the lymph nodes. Residual normal tissues were found in the testes
earch and Practice 212 (2016) 817–824 821
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nd parotid gland. The “starry sky” appearance and isolated colla-
en were observed in a few patients (Fig. 1).
.3. Results of immunohistochemistry, special histochemistry
taining, and genetic testing
Positive immunohistochemical results are shown in Table 3
Fig. 2A–E). Negative immunohistochemical results are shown in
able 4. Special histochemistry staining showed that the positive
ate of NAS-DCE was 55.6% (10/18, Fig. 2F). Of 11 patients who
eceived genetic testing, 3 had normal results. The ﬁndings of 8
atients with abnormal results are shown in Table 5.
.4. Diagnostic results
Thirty-nine patients were all diagnosed with MS (97.5%; all were
S) and one patient was diagnosed with primitive monocytic sar-
oma (2.5%). Tumors composed of three types of blood cells were
ot found in our series.
.5. Treatment
Twenty-ﬁve patients received treatment at our hospital;
mong whom, 12 underwent surgical resection (2 also received
adiotherapy). Fifteen patients received chemotherapy at our
ospital, mainly cytarabine. Cytarabine monotherapy was  admin-
stered to patients with poor disease conditions. Five patients
eceived lumbar puncture and intrathecal chemotherapy, among
hom, 1 patient had central nervous system involvement. Of
he four patients who underwent allo-HSCT, 2 died during
he post-transplant period (1–2 months). Pre-transplant treat-
ent with busulfan + cyclophosphamide was administered, and
yclosporine + mycophenolate mofetil + methotrexate was  given
or prevention of graft-versus-host disease (GVHD). Alterna-
ively, pre-transplant treatment was given with modiﬁed busul-
an + cyclophosphamide + antithymocyte globuli. Transplantation
as associated with risks including infections (opportunistic infec-
ions such as fungal/viral infections and cytomegalovirus viremia),
leeding, and GVHD, etc.
.6. Follow-up results
Follow-up was carried out in 18 patients for 10 months to 10
ears until November 22, 2015. The survival time ranged from 2
onths to 10 years (mean ± SD:33.9 ± 34.2 months). Seven patients
38.9%) are still alive. Their survival time ranged from 12 months to
0 years (mean ± SD: 51.9 ± 38.1 months). Among them, 1 patient
xperienced recurrence after 1 year of follow-up. Eleven patients
ied, yielding a fatality rate of 61.1%. Their survival time ranged
rom 2 to 54 months (mean ± SD: 18.1 ± 22.0 months). The dates
f death in 3 patients were unknown. Age and gender respectively
ith survival statistics had no signiﬁcance (P > 0.05). There were
o signiﬁcant difference of survival analysis between de-novo and
econdary MS  groups (P > 0.05); But 3 cases in de-novo group have
een survived more longer (72 months-10 years).
. Discussion
The etiology of MS  remains unknown. MS  may  occur in the
ollowing conditions. (1) MS  can occur preceding, concurrently
ith, or following myeloproliferative disorders including AML,
ML, MDS, multiple myeloma, or bone marrow ﬁbrosis; among
hich, AML  is particularly common, accounting for 46.3% of cases
2–4]. In our series, MS  occurred concurrently with leukemia in 9
ases, following AML  in 7, and following MDS  in 1 (total 43.6%).
2) In a small proportion of patients, MS  may  occur following bone Ta
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Table 5
Abnormal genetic testing results in 8 patients.
Cases Gene abnormalities
Case 1 NPM1 gene mutation
Cases 2 and 3 Positive AML-ETO fusion gene
Case 4 46, XY, t(1;22)(q12;q11)
Case 5 Positive SET/CAN fusion gene
Case 6 MLL-AF 10(+)
Case 7 Positive MLL/AF9 fusion gene and increased WT1  gene
expression. Karyotype: 39, XY,?t(1:2), −6, −9, −10, −12, −14,
−20,  −22/hypodiploid(41∼45)/46,XYCase 8 Karyotype 46, XY; results of karyotype analysis: 49,
XY,+8,+9,del(9)(q22) × 2, + 21[9]/49, sl,?del(7)(q32)[15]
marrow transplantation; typically at multiple sites. The European
Group for Blood and Marrow Transplantation retrospectively ana-
lyzed the incidence of GS following allo-HSCT for AML, CML  or MDS
in 5824 patients from 1981 to 1992 and found that 26 patients
(0.45%) developed GS 4–56 months after surgery [5]. In our series,
5 patients (12.8%) developed MS  11 months to 11 years after allo-
HSCT. Although the post-allo-HSCT incidence of MS is low, it does
pose a challenge to the future of this treatment. (3) MS is associated
with chemotherapy for lymphoma. Yang et al. [6] reported that 1
patient with conﬁrmed non-Hodgkin’s lymphoma (NHL) developed
MS after receiving 8 courses of high-dose chemotherapy. (4) MS
may  occur concurrently with lymphoma. In 1 patient, a mediasti-
nal mass was  diagnosed as lymphoblastic lymphoma (LBL), which
was conﬁrmed as MS  by cervical lymph node biopsy [6].
The tumor cells show diffuse proliferation and inﬁltration, and
some of them are arranged in a linear or Indian ﬁle pattern. Tumor
necrosis is rare. A varied number of residual original tissue struc-
tures are present; if the tumor cells have invaded the lymph nodes,
germinal centers are usually preserved. The presence of admixed
erythroid cells, megakaryocytes, or eosinophilic myelocytes is a
helpful clue to the possibility of a myeloid tumor [1–3,7]. Most
MS cells are small or medium-sized. They often have a small or
moderate amount of cytoplasm, weakly basophilic or eosinophilic.
The nuclear–cytoplasmic ratio is high. The nuclei may  be round,
oval, kidney-shaped, or lobulated, although some nuclei have an
irregular shape. The nuclear membrane is thick and the chromatin
is smooth. Some nuclei may  have 1 or 2 small but clearly deﬁned
nucleoli, and mitosis is visible [2,3,7]. In our series, the histological
ﬁndings were similar to the above features; in addition, an acinus-
like arrangement was  also observed. The starry sky appearance [3]
was also seen in some cases, with scattered collagen found within
the stroma. Cytoplasm was  abundant in most cases. In a few cases,
eccentric nuclei, nuclear grooves, signet ring-like or plasmacytoid
tumor cells were seen. Lymphocytic inﬁltration in the background
was observed in most cases. The cells varied in size, and cells at var-
ious stages of differentiation could be seen in a few cases. Almost
all of the patients had eosinophils inﬁtration. Because MS  arises
from myeloid blasts, eosinophils are frequently found rather than
lymphoma.
During the immunohistochemical examinations, MPO is the
most commonly used antibody for diagnosing MS.  It has high speci-
ﬁcity and sensitivity, with a positive rate of 83.6–100.0%. In fact,
MPO  is widely expressed in the myeloid lineages [3,7–10]. In our
series, the positive rate of MPO  was  92.1%. Lysozyme, CD68, CD43,
CD33, CD34 and CD117 also show myeloid differentiation [11].
CD43 has high sensitivity but low speciﬁcity. For tumor cells show-
ing similar morphology to NHL, if immunolabeling shows that the
cells are CD43-positive but CD3/CD20-negative, the possibility of
myeloid neoplasms should be considered. Myeloid markers and
other antibodies should be detected to conﬁrm the diagnosis [7].
MS  expresses at least 1 myeloid-associated antigen. It is reported
that the immunohistochemical positive rates of MS are: CD43,
earch 
8
C
5
2
e
R
N
e
o
C
a
T
B
g
o
c
s
a
C
c
g
h
s
i
t
w
o
m
C
s
m
n
a
o
l
a
d
o
w
a
f
a
t
e
a
C
e
c
e
a
a
(
c
d
i
a
S
c
i
c
sH.-Q. Wang, J. Li / Pathology – Res
5.7–100.0% [3,7]; lysozyme, 86.7–95.5%; CD68 (KP1), 85.0–95.2%;
D45, 90.8%; CD117, 77.8–90%; CD99, 58.7–81.5% [3,5,7]; CD15,
4.0–81%; CD34, 22.2–100.0%; TdT, 5.0–37.5%; CD56, 13.0%; CD61,
.2%; CD30, 2.2%; and CD4, 1.1% [3,7–9]. PAX5 is frequently
xpressed in some cases of AML  with t(8;21)(q22;q22)(RUNX1-
UNX1T1) [12]. The cytoplasm of GS cells was  stained red by
AS-DCE, showing obvious granular change. NAS-DCE is a speciﬁc
sterase and showed positive results in 55.6% of our patients. In
ur series, the positive rates of CD43, CD34, CD68, CD45, lysozyme,
D99, TdT and CD56 were similar to the above reported ﬁgures,
lthough the positive rate of CD117 (42.3%) was markedly lower.
he positive rates of other indicators in our series were as follows:
cl-2, 80% (8/10); CD38, 42.9% (3/7); and PAX-5, 12.5% (1/8), no
ene test.
In the current study, 5 cases didn’t checked the expression
f CD20 with CD5, in which 4 ones didn’t test CD3. All of the
ases were secondary to AML. The patients all showed the expres-
ion of MPO, in which 3 case expressed CD34 with 1 case CD68+,
nd the other 2 showed CD68 + with CD34−. MPO, CD34 and
D68 all implied myeloid differentiation. Histologically, tumor
ells differentiated to myelocyte and metamyelocyte. Eosinophilic
ranulocyte inﬁltrated. MS  were diagnosed according to medical
istory, histology features and immunohistochemistry. Because of
mall needle biospy plus the economic factor, more indexes of
mmunohistochemistry check can,t been done.
In our series, there are 3 case MPO− with CD43+ and nega-
ive of B and T cell markers. 2 cases were secondary to AML, in
hich 1 patient with CD34+ and CD117+ had allo-HSCT hisory. The
ther was de-novo MS  with CD34+ and TDT−; Some clues showed
yeloid differentiation: about 15% cells of the patient also express
D68; naive eosinophilic granulocyte were seen; eccentric, kidney-
haped, and lobulated nuclei were observed; there are also a few of
ultinucleated and giant cells. Tumor cells of MPO- patients were
aive, differentiating to blastic type. Nuclear chromatin was ﬁne,
nd obvious small nucleoli were seen. Background were found a few
f mature and or childish eosinophilic cells. Meeting a case of the
ymphoid and hematological system with MPO−, CD43+, and neg-
tive of B and T cell markers, we comprehensively make a correct
iagnose though combining medical history and tissue morphol-
gy, especially native and or mature esonophils inﬁltration. In the
hile, other myeloid markers also suggested diagnosis clues such
s CD34, CD117, CD68, etc.
Research has suggested that CD68 (PG-M1) is a speciﬁc marker
or primitive monocytic sarcoma and is helpful in differentiating GS
nd primitive monocytic sarcoma [3]. In two patients with primi-
ive monocytic sarcoma, CD45, lysozyme and CD68 were positively
xpressed, whereas MPO  and CD34 were negative [3]. Other char-
cteristic antigens for monocyte series include CDl4, CD64, CD36,
D11b and CD11c,CD163. Nonspeciﬁc esterase was positively
xpressed in monocytic series [1]. For the rare myeloid lesions
omposed of immature erythroid cells or megakaryocytes, anti-
rythrocyte hemoglobin A and glycoprotein antibody, as well as
nti-megakaryocytic von Willebrand factor (factor-VIII-associated
ntigen), CD41, CD61 and CD31 antibodies may  be used [2].
Pileri et al. [9] found that monosomy 7 (10.8%), trisomy 8
10.4%) and mixed lineage leukemia-splitting (8.5%) were the most
ommon chromosomal aberrations. In our series, trisomy 8 was
etected in 1 patient; In the while, rare genetic abnormalities
ncluding increased WT-1 gene expression, NPM1 gene mutation,
s well as the occurrence of fusion genes including AML-ETO,
ET/CAN, MLL-AF10 and MLL/AF9 were also found in the series.
The clinical features, radiographic features, immunohisto-
hemical markers, and cytogenetic features should be taken
nto consideration during diagnosis of MS  [13]. The role of
ytogenetics has become increasingly important [4]. Positron emis-
ion/computed tomography (PET-CT) is a useful diagnostic tool inand Practice 212 (2016) 817–824 823
determining the location of MS  [14]. MS  is frequently misdiagnosed
and needs to be differentiated from the following diseases. (1) NHL.
There are some morphological similarities between MS  and NHL:
both have diffuse inﬁltration of scattered tumor cells. However,
immature granulocyte inﬁltration and an Indian ﬁle arrange-
ment pattern can be seen in MS,  along with negative lymphocyte
antigens including CD3, CD20, CD79a and PAX-5, and positive
myeloid differentiation antigens (e.g. MPO). TdT is positive in a
few MS  cases, which should be differentiated from LBL/leukemia.
LBL/leukemia can express lymphocyte-associated antigens, along
with high Ki67 index (often >90%). In a few LBL/leukemia cases, the
starry sky appearance is visible, whereas the nucleolus is lacking.
CD30 is positive in a few MS  cases, which need to be differenti-
ated from anaplastic large cell lymphoma (ALCL). Kidney-shaped
nuclei are present in both MS  and NHL, which makes differen-
tial diagnosis even more difﬁcult. Polymorphism of tumor cells
and immunohistochemistry may  facilitate the diagnosis of ALCL.
(2) Primitive neuroectodermal tumor (PNET)/extraosseous Ewing’s
sarcoma (EES). Both MS  and PNET/EES have positive CD99 expres-
sion and similar cell size and morphology. However, PNET/ESS is
often manifested as a soft tissue mass, showing lobulated or nodular
arrangement, and formation of rosettes. Necrotic tissue is common,
and the cytoplasm is small and stained pale, or transparent. Neu-
ron speciﬁc endolase (NSE), Synaptophysin (Syn) and cytokeratin
(CK) were positive in varying degrees and special histochemistry
staining of periodic acid–Schiff also showed positive result. Most
patients with PNET/EES have t(11;22) (q24;q12) translocation or
EWS-ERG gene fusion. (3) Embryonal rhabdomyosarcoma, neu-
roendocrine carcinoma, and invasive lobular carcinoma of the
breast, etc. Morphology, immunohistochemistry and clinical fea-
tures help with the differential diagnosis in these diseases.
Li et al. [3] reported that de-novo MS  yielded 30.5% (25/82),
average for 37.6 years, and 18 cases under 50 years old (72.0%). 4
cases survived with no diseases during the follow-up time for 5–52
months. But there were no signiﬁcant difference for survival anal-
ysis between secondary and de-novo groups. In our series, female
radio was higher in the de-novo group than the secondary group
(64.3% vs. 29.4%), older average years (41.4 vs. 31.1 years), older
middle years (47.5 vs.32 years), but no signiﬁcant difference for sur-
vival analysis. The results were similar to Li et al. [3] report. Meis
et al. [15] reported 4 cases of 16 de-novo GS had been survived
for 3.5–16 years with no disease reoccur. In our study, 3 cases in
de-novo MS  group have been survived for 72 months to 10 years.
For MS  treatment, chemotherapy is more effective than radi-
ation or surgical resection [13]. Treatment response and median
survival are not affected by the following factors: age, gen-
der, anatomical location, tissue type, phenotype, cytogenetics,
and potential AML  or myeloproliferative disease [8]. Treatment
strategies are to a large extent dependent on the stage of
disease development (e.g. initial diagnosis or recurrence). Inten-
sive chemotherapy is necessary for early MS,  whereas induction
chemotherapy may  be more effective for recurrent MS  [13,16].
However, active induction chemotherapy can be poorly tolerated
by elderly patients and may lead to a high case-fatality rate [13]. In
our series, most patients received chemotherapy (as for AML). MS
was detected at 2 sites in 1 patient, although bone marrow aspi-
ration did not show any abnormality. The patient did not receive
chemotherapy, and survived for 10 years in good condition; recent
examinations showed the presence of anemia and splenomegaly.
Allo-HSCT is a promising treatment for MS.  Al-Khateeb et al. [8]
found that patients who had undergone allo-HSCT had signiﬁcantly
longer mean survival time than those who  had not received bone
marrow transplantation (58.6 vs. 11.1 months, respectively). The
common complications of allo-HSCT include GVHD, opportunis-
tic infections, and bleeding in our series. An immune regulation
stage during the implantation period is particularly dangerous.
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myeloid malignancy, Leuk. Res. 34 (2010) 1239–1241.
[15] J.M. Meis, J.J. Butler, B.M. Osborne, J.T. Manning, Granulocytic sarcoma in24 H.-Q. Wang, J. Li / Pathology – Res
n our series, 2 patients died during the implantation stage: one
ied of respiratory failure caused by mixed infections and multi-
le organ injury, and the other died of cerebral and gastrointestinal
emorrhage following Ochrobactrum anthropi bacteremia and dis-
eminated candidiasis. In our series, a total of 9 patients underwent
llo-HSCT.
The prognosis of MS  is poor. The survival time is generally
hort, although it has varied markedly among different studies. Al-
hateeb et al. [8] reported a median survival of 24.7 months. Li et al.
3] found that the mean survival time was 47.3 months, median
urvival time was 14 months, and the 1-, 2- and 5-year survival
ates were 56.0%, 36.1% and 17.3%. Liu et al. [7] followed up 18
atients; 14 of whom died within 1–24 months after their disease
as conﬁrmed. Early diagnosis and appropriate treatment strate-
ies should be implemented before the disease progresses to AML,
hereby ensuring better prognosis [13]. The selection of treatments
s somewhat correlated with prognosis. In our series, the median
urvival time was 28.0 months and the mean survival time was  33.9
onths.
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